News

The FDA has approved Saphris tablets (asenapine) to treat adults with schizophrenia and bipolar I disorder. The efficacy of Saphris in treating schizophrenia was studied in three short-term

Biostar Pharmaceuticals has posted revenue of $13.2m for the second quarter of 2009, an increase of 40.6% compared to $9.4m for the second quarter of 2008. The company

FDA has approved Schering-Plough’s SAPHRIS (asenapine) sublingual tablets for acute treatment of schizophrenia and manic or mixed episodes, associated with bipolar I disorder with or without psychotic features,

GSK has issued an update on its progress to develop a vaccine against the Pandemic (H1N1) 2009 influenza virus. The company has also commenced the clinical development program

DOR’s revenues, for the second quarter of 2009, were approximately $0.3m compared to $0.5m for the second quarter of 2008. Revenues for the first half of 2009 were

The FDA has advised health care practitioners and patients against using certain glucose monitoring technology, that employs a specific test strip when the patients are also receiving therapeutic

China Shenghuo has reported an increase of 2.36% in the gross profits to $5.7m for the second quarter, as against $5.6m for the same period in 2008. For

Ziopharm has reported its financial results for the quarter ended June 30, 2009. The company reported a net loss of $2.4m, or $(0.11) per share, for the second

FDA has approved DNage’s Investigational New Drug application for Prodarsan, allowing the company to initiate a clinical trial in children suffering from Cockayne Syndrome (CS). DNage is a